Contera Pharma
Contera Pharma is a Danish biotech company dedicated to developing innovative therapies for neurological disorders. They focus on creating a de-risked portfolio of projects targeting validated human disease mechanisms, aiming to improve life for patients with complex neurological conditions. Their mission involves applying platform technology and scientific expertise to discover and develop novel treatments, including antisense oligonucleotides and small molecules, with a strong emphasis on precision medicine and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
Contera Pharma
Venlighedsvej 4, 2970 Hørsholm, Denmark
Patents
Combinations of serotonin receptor agonists for treatment of movement disorders
US-10632116-B2
View DetailsOrally available pharmaceutical formulation suitable for improved management of movement disorders
US-10561618-B2
View DetailsCombinations of serotonin receptor agonists for treatment of movement disorders
US-9186359-B2
View Details
Combinations of serotonin receptor agonists for treatment of movement disorders
US-10632116-B2
View DetailsOrally available pharmaceutical formulation suitable for improved management of movement disorders
US-10561618-B2
View DetailsCombinations of serotonin receptor agonists for treatment of movement disorders
US-9186359-B2
View DetailsProducts
JM-010
Small-molecule clinical-stage candidate developed to treat levodopa-induced dyskinesia in Parkinson’s disease; progressed through Phase I and proof-of-concept studies and advanced into Phase II clinical testing across multiple regions.
CP-012
Delayed-release, dual-pulse oral levodopa/carbidopa tablet developed to address nocturnal immobility and early morning akinesia in Parkinson’s disease; evaluated in a Phase 1b pharmacoscintigraphic study.
CP0014753 (antisense oligonucleotide candidate)
First-in-class antisense oligonucleotide preclinical candidate nominated to modulate expression of a gene implicated in Canavan disease; progression to IND-enabling studies planned.
JM-010
Small-molecule clinical-stage candidate developed to treat levodopa-induced dyskinesia in Parkinson’s disease; progressed through Phase I and proof-of-concept studies and advanced into Phase II clinical testing across multiple regions.
CP-012
Delayed-release, dual-pulse oral levodopa/carbidopa tablet developed to address nocturnal immobility and early morning akinesia in Parkinson’s disease; evaluated in a Phase 1b pharmacoscintigraphic study.
CP0014753 (antisense oligonucleotide candidate)
First-in-class antisense oligonucleotide preclinical candidate nominated to modulate expression of a gene implicated in Canavan disease; progression to IND-enabling studies planned.
Services
Sourcing, evaluating and negotiating collaborations or in-licensing deals for proprietary assets and platform technologies, with a current focus on neurological disorders.
Joint discovery collaborations applying explainable AI models and automated RNA design to identify targets and generate ASO/siRNA candidates for rare neurological diseases.
Sourcing, evaluating and negotiating collaborations or in-licensing deals for proprietary assets and platform technologies, with a current focus on neurological disorders.
Joint discovery collaborations applying explainable AI models and automated RNA design to identify targets and generate ASO/siRNA candidates for rare neurological diseases.
Expertise Areas
- RNA therapeutics (antisense oligonucleotides and siRNA)
- Neurology drug discovery and development
- Precision medicine target identification
- Early-stage clinical development (Phase I/II)
Key Technologies
- Antisense oligonucleotide therapeutics
- siRNA therapeutics
- Explainable machine learning for target identification
- Automated RNA therapeutic design workflows
News & Updates
Contera Pharma announced the readiness of CP0014753 for IND-enabling studies, a significant step in developing treatments for Canavan disease.
The company announced the addition of new members to its Board of Directors to support strategic development and growth.
Contera Pharma announced the dosing of the first patient in a Phase 1b trial of CP-012, aimed at treating nocturnal immobility and morning akinesia in Parkinson’s disease.
Contera Pharma announced the readiness of CP0014753 for IND-enabling studies, a significant step in developing treatments for Canavan disease.
The company announced the addition of new members to its Board of Directors to support strategic development and growth.
Contera Pharma announced the dosing of the first patient in a Phase 1b trial of CP-012, aimed at treating nocturnal immobility and morning akinesia in Parkinson’s disease.